Content about Buddhism

January 2, 2014

Drug maker Eisai will make a new epilepsy drug available in the United States starting on Monday, the company said.

WOODCLIFF LAKE, N.J. — Drug maker Eisai will make a new epilepsy drug available in the United States starting on Monday, the company said Thursday.

September 12, 2013

Drug maker Eisai has launched a new support and savings program for patients using a weight-loss drug that it makes.

WOODCLIFF LAKE, N.J. — Drug maker Eisai has launched a new support and savings program for patients using a weight-loss drug that it makes.

The drug maker announced Thursday the availability of Believe Everyday Support for patients using Belviq (lorcaserin hydrochloride), which includes a customizable online portal designed to help patients reach their weight loss goals and sustain their efforts.

August 15, 2013

Eisai, the U.S. pharmaceutical arm of Tokyo-based Eisai Co., announced the launch of a new website, "Closing the Gap: Obesity Management for Employers," to provide employers with an educational resource for information about obesity management.

WOODCLIFF LAKE, N.J. — Eisai Inc., the U.S. pharmaceutical arm of Tokyo-based Eisai Co. Ltd., announced on Thursday the launch of a new website, "Closing the Gap: Obesity Management for Employers," to provide employers with an educational resource for information about obesity management.

February 21, 2013

Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

WOODCLIFF LAKE, N.J. — Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.

Valeant has bought the rights to Targretin (bexarotene) capsules and gel from Eisai for $65 million upfront, plus additional payments based on certain milestones. Under the deal, Eisai has transferred its regulatory approval application to Valeant, which will assume responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain rights to the drug outside the United States.

July 29, 2011

The Food and Drug Administration has asked Eisai to redo its regulatory application for a drug to treat epilepsy, Eisai said Friday.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has asked Eisai to redo its regulatory application for a drug to treat epilepsy, Eisai said Friday.

The drug maker said the FDA issued a refusal to file letter in response to its application for perampanel, designed to treat partial-onset seizures in patients with epilepsy. In the letter, the FDA requested reformatting and reanalyses of some datasets, though Eisai said new studies probably were unnecessary.

March 4, 2011

The Food and Drug Administration has approved a drug made by Eisai to treat a rare form of epilepsy, the drug maker said Friday.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a drug made by Eisai to treat a rare form of epilepsy, the drug maker said Friday.

The FDA approved Banzel (rufinamide) oral suspension for the treatment of seizures in children and adults with Lennox-Gastaut syndrome. The condition, also called LGS, affects 1% to 4% of children with epilepsy.

“This new formulation provides an option for patients who may prefer a liquid or find it difficult to take the medication in tablet form,” Eisai president and CEO Lonnel Coats said.